Outsourcing sequencing analysis of samples for projects CSBabyBiome and Lifelines-NEXT
The University Medical Center Groningen (UMCG) intends to outsource the sequencing analysis of samples for the CSBabyBiome and Lifelines-NEXT projects to Novogene. To minimize bias caused by sample preparation and data generation, the same facility, the same platform, and the same methodology must be used for all sample types (gut microbiome, gut virome, breast milk, vaginal microbiome). The procurement is subject to a negotiated procedure without prior publication; this announcement serves as voluntary transparency and provides market parties the opportunity to lodge an objection within 20 days. After the objection period, the procedure will continue, typically resulting in an award to Novogene.
Services · Onderhandeling zonder bekendmaking · European procedure
01What is being requested
The University Medical Center Groningen (UMCG) intends to outsource the sequencing analysis of samples for the CSBabyBiome and Lifelines-NEXT projects to Novogene. To minimize bias caused by sample preparation and data generation, the same facility, the same platform, and the same methodology must be used for all sample types (gut microbiome, gut virome, breast milk, vaginal microbiome). The procurement is subject to a negotiated procedure without prior publication; this announcement serves as voluntary transparency and provides market parties the opportunity to lodge an objection within 20 days. After the objection period, the procedure will continue, typically resulting in an award to Novogene.
This concerns the voluntary transparency of the intention to award a contract for outsourcing sequencing analysis for the Genetics department of the University Medical Center Groningen (UMCG). The Genetics department has had samples sequenced by Novogene for the CSBabyBiome and Lifelines-NEXT projects. For further research, it is important that the remaining samples are processed in the same facility using the same platform. This is to minimize bias caused by sample preparation and data generation. Consistent use of the same methodology and equipment across different samples (gut microbiome, g
02Exclusion grounds
- No specific exclusion grounds were extracted. In a European tender, the mandatory and discretionary grounds of art. 2.86/2.87 of the Dutch Procurement Act almost always apply — check the European Single Procurement Document (ESPD).
03Value in context
The contracting authority did not publish an estimated value — common for a large share of contracts. The EU threshold for diensten is € 221.000, for reference.
04Likely competitors
05Legal themes that may be relevant here
06Frequently asked questions
What is the reason for the intended choice of Novogene?
How can stakeholders object to this procedure?
Automatically compiled from the official tender data and documents.
07Estimated value versus the market
€ 962K
€ 16 mln
€ 108 mln
Gegunde waarden in CPV 85 · diensten n=1531